tiprankstipranks
Innate Pharma announces results from TELLOMAK study
PremiumThe FlyInnate Pharma announces results from TELLOMAK study
6M ago
Innate Pharma provides clarification regarding SAR443579 designation
Premium
The Fly
Innate Pharma provides clarification regarding SAR443579 designation
6M ago
Innate Pharma doses first patient in Sanofi-sponsored trial of SAR443579
Premium
The Fly
Innate Pharma doses first patient in Sanofi-sponsored trial of SAR443579
7M ago
Innate Pharma CEO Mondher Mahjoubi resigns, Herve Brailly appointed interim CEO
PremiumThe FlyInnate Pharma CEO Mondher Mahjoubi resigns, Herve Brailly appointed interim CEO
11M ago
Innate announces updated efficacy, safety results from SAR443579 / IPH6101 study
Premium
The Fly
Innate announces updated efficacy, safety results from SAR443579 / IPH6101 study
12M ago
Innate Pharma announces partial clinical hold on lacutamab IND placed by FDA
Premium
The Fly
Innate Pharma announces partial clinical hold on lacutamab IND placed by FDA
1y ago
Innate Pharma highlights increased lacutamab activity in TELLOMAK study
PremiumThe FlyInnate Pharma highlights increased lacutamab activity in TELLOMAK study
1y ago
Innate Pharma establishes at-the-market program on Nasdaq for up to $75M
Premium
The Fly
Innate Pharma establishes at-the-market program on Nasdaq for up to $75M
2y ago
Innate Pharma price target raised to $10 from $9 at SVB Securities
Premium
The Fly
Innate Pharma price target raised to $10 from $9 at SVB Securities
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100